{"id":"etilamfetamine","rwe":[{"pmid":"25618172","year":"2015","title":"Driving under the influence of synthetic phenethylamines: a case series.","finding":"","journal":"International journal of legal medicine","studyType":"Clinical Study"},{"pmid":"3790195","year":"1986","title":"The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"etilamfetamine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"A08AA06","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"apetinil","offLabel":[],"synonyms":["etilamfetamine","(+/-)-Ethylamphetamine","2-Ethylamino-1-phenylpropane","apetinil","ethylamphetamine","N-Ethylamphetamine","ethylamphetamine hydrochloride","ethylamphetamine HCl"],"timeline":[],"approvals":[],"brandName":"Apetinil","ecosystem":[],"mechanism":{"target":"Sigma non-opioid intracellular receptor 1","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"}],"modality":"Small Molecule","drugClass":"etilamfetamine","explanation":"Think of it like a key fitting into a lock. Apetinil is the key that binds to the Sigma receptor, which helps regulate how our cells respond to certain signals. This can affect things like pain perception, mood, and other bodily functions.","oneSentence":"Apetinil works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various physiological processes.","technicalDetail":"Apetinil exerts its effects by interacting with the sigma-1 receptor, a subtype of the sigma receptor family, which is implicated in modulating cellular processes such as neurotransmitter release and intracellular signaling pathways."},"commercial":{"revenueYear":2025,"annualRevenue":172,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1100","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETILAMFETAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:17:07.410131","biosimilars":[],"competitors":[{"drugName":"phentermine","drugSlug":"phentermine","fdaApproval":"1959-05-04","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenfluramine","drugSlug":"fenfluramine","fdaApproval":"2020-06-25","patentExpiry":"Nov 3, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"diethylpropion","drugSlug":"diethylpropion","fdaApproval":"1959-08-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mazindol","drugSlug":"mazindol","fdaApproval":"1973-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sibutramine","drugSlug":"sibutramine","fdaApproval":"1997-11-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"lorcaserin","drugSlug":"lorcaserin","fdaApproval":"2012-06-27","relationship":"same-class"},{"drugName":"setmelanotide","drugSlug":"setmelanotide","fdaApproval":"2020-11-25","patentExpiry":"Oct 13, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ephedrine","drugSlug":"ephedrine","fdaApproval":"","patentExpiry":"May 16, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"etilamfetamine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phentermine","brandName":"phentermine","genericName":"phentermine","approvalYear":"1959","relationship":"same-class"},{"drugId":"fenfluramine","brandName":"fenfluramine","genericName":"fenfluramine","approvalYear":"2020","relationship":"same-class"},{"drugId":"diethylpropion","brandName":"diethylpropion","genericName":"diethylpropion","approvalYear":"1959","relationship":"same-class"},{"drugId":"mazindol","brandName":"mazindol","genericName":"mazindol","approvalYear":"1973","relationship":"same-class"},{"drugId":"sibutramine","brandName":"sibutramine","genericName":"sibutramine","approvalYear":"1997","relationship":"same-class"},{"drugId":"lorcaserin","brandName":"lorcaserin","genericName":"lorcaserin","approvalYear":"2012","relationship":"same-class"},{"drugId":"setmelanotide","brandName":"setmelanotide","genericName":"setmelanotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-class"},{"drugId":"ephedrine","brandName":"ephedrine","genericName":"ephedrine","approvalYear":"","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"022YON1XMX","CHEBI":"CHEBI:134796","INN_ID":"4532","UMLSCUI":"C0059791","ChEMBL_ID":"CHEMBL276443","KEGG_DRUG":"D07114","DRUGBANK_ID":"DB13285","PUBCHEM_CID":"9982","SNOMEDCT_US":"786882006","MESH_SUPPLEMENTAL_RECORD_UI":"C016434"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Pain"],"_revenueScrapedAt":"2026-03-31 14:09:35.487336+00","atcClassification":{"source":"DrugCentral","atcCode":"A08AA06","allCodes":["A08AA06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2015 Sep","pmid":"25618172","title":"Driving under the influence of synthetic phenethylamines: a case series.","journal":"International journal of legal medicine"},{"date":"1986 Sep","pmid":"3790195","title":"The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apetinil (Etilamfetamine) is a small molecule drug that targets the Sigma non-opioid intracellular receptor 1. It is classified as an etilamfetamine, but its commercial status and approved indications are unknown. The mechanism of action and pharmacokinetic properties of Apetinil are also not well-documented. Further research is needed to fully understand the potential benefits and risks of this medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}